Lexicon Pharmaceutcl (LXRX)

$2.55 +0.26 (11.35%)
Market Cap 1.13B
Revenue (ttm) 49.80M
Net Income (ttm) -50.34M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -101.08%
Debt to Equity Ratio 0.24
Volume 39,463,801
Avg Vol 3,309,908
Day's Range N/A - N/A
Shares Out 444.20M
Stochastic %K 100%
Beta 1.06
Analysts Sell
Price Target $3.77

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospit...

Industry: Biotechnology
Sector: Healthcare
Phone: 281 863 3000
Fax: 281 863 8088
Address:
2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States
atreus57
atreus57 Jun. 29 at 10:53 AM
$LXRX looks like another positive day... more to come, there is a lot of room up there...
0 · Reply
TracR
TracR Jun. 29 at 7:06 AM
$LXRX Filing PR is overrated imho. Mike said they'd file so my guess is, its priced in. Might even be a sell-the-news event. What happens 6 months from the day they file though is another story.
0 · Reply
Kocatka
Kocatka Jun. 29 at 1:24 AM
$LXRX https://fintel.io/ss/us/lxrx
0 · Reply
BullriderNkg
BullriderNkg Jun. 28 at 11:49 PM
$LXRX New highs, end of the month, great volume on Friday. Was it Russel madness, Zynquista news coming? I sure do appreciate it.... now lets see something!!!
0 · Reply
Thekareemofthecrop
Thekareemofthecrop Jun. 28 at 1:55 PM
$LXRX is there any benefit to dropping the PR after the Russell rebalancing?
2 · Reply
Jas7235355
Jas7235355 Jun. 27 at 6:36 PM
$LXRX Maybe but where did last minute volumes come from???
1 · Reply
Cat651
Cat651 Jun. 27 at 10:04 AM
$LXRX IS It time already to visit 3'9/4$? Strong weekly close with huge Volume
0 · Reply
stefano62
stefano62 Jun. 27 at 9:53 AM
$LXRX do you think monday morning Will exit the PR About the Zynquista resubmission?
3 · Reply
Achouffe
Achouffe Jun. 27 at 7:58 AM
$LXRX
0 · Reply
Badstick
Badstick Jun. 27 at 3:58 AM
$LXRX Super long here and worth it!
0 · Reply
Latest News on LXRX
Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 2:00 PM EDT - 24 days ago

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Jun 3, 2026, 8:00 AM EDT - 25 days ago

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 28, 2026, 8:30 AM EDT - 4 weeks ago

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals Slides: Investor presentation

May 26, 2026, 7:00 AM EDT - 4 weeks ago

Lexicon Pharmaceuticals Slides: Investor presentation

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 4:30 PM EDT - 5 weeks ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

May 12, 2026, 8:30 AM EDT - 6 weeks ago

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon price target raised to $3.10 from $2.30 at Citi

2026-05-11T11:01:50.000Z - 7 weeks ago

Lexicon price target raised to $3.10 from $2.30 at Citi

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026

Lexicon Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals Earnings release: Q1 2026

Lexicon Pharmaceuticals Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals Slides: Q1 2026

Lexicon Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 8:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals Quarterly report: Q1 2026

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

May 7, 2026, 7:30 AM EDT - 7 weeks ago

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

May 4, 2026, 4:05 PM EDT - 7 weeks ago

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

HTGC

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

Lexicon to present data at AAN annual meeting on Progress Phase 2b study

2026-04-17T12:22:28.000Z - 2 months ago

Lexicon to present data at AAN annual meeting on Progress Phase 2b study

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Apr 17, 2026, 8:00 AM EDT - 2 months ago

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Mar 24, 2026, 8:00 AM EDT - 3 months ago

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

Lexicon, Novo Nordisk announce initiation of LX9851 study

2026-03-23T11:46:37.000Z - 3 months ago

Lexicon, Novo Nordisk announce initiation of LX9851 study

NVO

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Mar 23, 2026, 7:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Lexicon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 10:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

Lexicon announces results from post hoc analysis on data of sotagliflozin

2026-03-11T12:17:17.000Z - 3 months ago

Lexicon announces results from post hoc analysis on data of sotagliflozin

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

Mar 11, 2026, 8:00 AM EDT - 3 months ago

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

Lexicon price target raised to $2.30 from $2.10 at Citi

2026-03-10T10:53:36.000Z - 3 months ago

Lexicon price target raised to $2.30 from $2.10 at Citi

Lexicon price target raised to $6 from $4 at H.C. Wainwright

2026-03-05T16:06:30.000Z - 4 months ago

Lexicon price target raised to $6 from $4 at H.C. Wainwright

Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025

Lexicon Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Annual report: Q4 2025

Lexicon Pharmaceuticals Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Earnings release: Q4 2025

Lexicon Pharmaceuticals Slides: Q4 2025

Mar 5, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals Slides: Q4 2025

Lexicon reports Q4 EPS (4c), consensus (7c)

2026-03-05T12:08:49.000Z - 4 months ago

Lexicon reports Q4 EPS (4c), consensus (7c)

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Mar 5, 2026, 6:59 AM EST - 4 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

Mar 3, 2026, 4:01 PM EST - 4 months ago

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

Feb 26, 2026, 8:30 AM EST - 4 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Feb 17, 2026, 7:00 AM EST - 4 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Feb 6, 2026, 5:17 PM EST - 5 months ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 30, 2026, 2:50 AM EST - 5 months ago

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Lexicon announces common stock offering, no amount given

2026-01-29T21:36:16.000Z - 5 months ago

Lexicon announces common stock offering, no amount given

Lexicon Announces Proposed Public Offering of Common Stock

Jan 29, 2026, 4:31 PM EST - 5 months ago

Lexicon Announces Proposed Public Offering of Common Stock

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

Jan 23, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

Lexicon completes End-of-Phase 2 meeting with U.S. FDA for pilavapadin

2026-01-21T13:42:01.000Z - 5 months ago

Lexicon completes End-of-Phase 2 meeting with U.S. FDA for pilavapadin

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Jan 21, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

Jan 20, 2026, 6:59 AM EST - 5 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

VTRS

Lexicon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 3:00 PM EST - 5 months ago

Lexicon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Lexicon Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 3:00 PM EST - 5 months ago

Lexicon Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

Lexicon price target raised to $2.10 from $1.90 at Citi

2026-01-14T10:45:10.000Z - 5 months ago

Lexicon price target raised to $2.10 from $1.90 at Citi

Lexicon sees cash runway into 2027

2026-01-12T12:55:44.000Z - 5 months ago

Lexicon sees cash runway into 2027

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 7:30 AM EST - 5 months ago

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

Lexicon publishes White Paper on treatments for chronic pain

2026-01-09T13:40:14.000Z - 6 months ago

Lexicon publishes White Paper on treatments for chronic pain

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

Jan 9, 2026, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Lexicon announces publication of preclinical data on ACSL5

2025-12-10T13:40:17.000Z - 7 months ago

Lexicon announces publication of preclinical data on ACSL5

NVO

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Dec 10, 2025, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Dec 5, 2025, 8:30 AM EST - 7 months ago

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Lexicon Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 4, 2025, 9:10 AM EST - 7 months ago

Lexicon Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Lexicon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 9:00 AM EST - 7 months ago

Lexicon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Nov 25, 2025, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Lexicon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 12:00 PM EST - 7 months ago

Lexicon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Lexicon Pharmaceuticals Slides: Corporate presentation

Nov 14, 2025, 7:00 AM EST - 8 months ago

Lexicon Pharmaceuticals Slides: Corporate presentation

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Nov 11, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025

2025-11-09T18:20:08.000Z - 8 months ago

Lexicon announces new sotagliflozin clinical data at AHA Sessions 2025

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Nov 8, 2025, 2:30 PM EST - 8 months ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2025

Lexicon Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Quarterly report: Q3 2025

Lexicon Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Earnings release: Q3 2025

Lexicon Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Slides: Q3 2025

Lexicon reports Q3 EPS (4c), consensus (7c)

2025-11-06T12:41:13.000Z - 8 months ago

Lexicon reports Q3 EPS (4c), consensus (7c)

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Nov 6, 2025, 7:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Nov 4, 2025, 8:30 AM EST - 8 months ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 30, 2025, 8:30 AM EDT - 8 months ago

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 14, 2025, 8:00 AM EDT - 9 months ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Oct 8, 2025, 7:59 AM EDT - 9 months ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 22, 2025, 4:00 PM EDT - 9 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 17, 2025, 7:00 AM EDT - 10 months ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 11, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 2:30 PM EDT - 10 months ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 8, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 4, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Lexicon Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 1:45 PM EDT - 10 months ago

Lexicon Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 3, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Sep 2, 2025, 8:30 AM EDT - 10 months ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 27, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2025

Lexicon Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Quarterly report: Q2 2025

Lexicon Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Earnings release: Q2 2025

Lexicon Pharmaceuticals Slides: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Slides: Q2 2025

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 6, 2025, 7:30 AM EDT - 11 months ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 31, 2025, 8:00 AM EDT - 11 months ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Lexicon Pharmaceuticals Slides: Corporate Presentation

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Corporate Presentation

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 1 year ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

May 29, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 9:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

May 19, 2025, 8:00 AM EDT - 1 year ago

SONATA-HCM Study Design Presented at Heart Failure 2025, the Annual Congress of the Heart Failure Association of the European Society of Cardiology

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2025

Lexicon Pharmaceuticals Quarterly report: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Quarterly report: Q1 2025

Lexicon Pharmaceuticals Earnings release: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings release: Q1 2025

Lexicon Pharmaceuticals Slides: Q1 2025

May 13, 2025, 5:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Q1 2025

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

May 13, 2025, 4:00 PM EDT - 1 year ago

Lexicon Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Updates

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

May 6, 2025, 4:30 PM EDT - 1 year ago

Lexicon Pharmaceuticals to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference

atreus57
atreus57 Jun. 29 at 10:53 AM
$LXRX looks like another positive day... more to come, there is a lot of room up there...
0 · Reply
TracR
TracR Jun. 29 at 7:06 AM
$LXRX Filing PR is overrated imho. Mike said they'd file so my guess is, its priced in. Might even be a sell-the-news event. What happens 6 months from the day they file though is another story.
0 · Reply
Kocatka
Kocatka Jun. 29 at 1:24 AM
$LXRX https://fintel.io/ss/us/lxrx
0 · Reply
BullriderNkg
BullriderNkg Jun. 28 at 11:49 PM
$LXRX New highs, end of the month, great volume on Friday. Was it Russel madness, Zynquista news coming? I sure do appreciate it.... now lets see something!!!
0 · Reply
Thekareemofthecrop
Thekareemofthecrop Jun. 28 at 1:55 PM
$LXRX is there any benefit to dropping the PR after the Russell rebalancing?
2 · Reply
Jas7235355
Jas7235355 Jun. 27 at 6:36 PM
$LXRX Maybe but where did last minute volumes come from???
1 · Reply
Cat651
Cat651 Jun. 27 at 10:04 AM
$LXRX IS It time already to visit 3'9/4$? Strong weekly close with huge Volume
0 · Reply
stefano62
stefano62 Jun. 27 at 9:53 AM
$LXRX do you think monday morning Will exit the PR About the Zynquista resubmission?
3 · Reply
Achouffe
Achouffe Jun. 27 at 7:58 AM
$LXRX
0 · Reply
Badstick
Badstick Jun. 27 at 3:58 AM
$LXRX Super long here and worth it!
0 · Reply
BarclayMullins
BarclayMullins Jun. 27 at 3:11 AM
$LXRX am I still early here ? Just found this tonight
1 · Reply
PatienceIsLambo
PatienceIsLambo Jun. 27 at 3:10 AM
$LXRX what caused the volume jump 4pm hmmmm, off HOD.. SOMEONE KNOWS SOMETHING?
2 · Reply
topstockalerts
topstockalerts Jun. 27 at 2:01 AM
$LXRX this stock is showing a lot more character than I expected.
0 · Reply
Mister_Bungle
Mister_Bungle Jun. 27 at 12:57 AM
$SLS & $LXRX are going to be the reason I retire at 44. God bless both these companies 🙏🏻💰
2 · Reply
GenericPoster
GenericPoster Jun. 27 at 12:17 AM
$LXRX What AI (Gemini) says about next week’s trading; espeically in light of today’s Russell rebalancing and huge Market on Close orders. I also asked AI (Gemini) about whether the well telegraphed Zynquista would be a ‘sell the news’ event and whether the resubmission required a PR:
0 · Reply
gucag006
gucag006 Jun. 26 at 11:23 PM
$LXRX Now what!
0 · Reply
CatchTheCleanUpSet
CatchTheCleanUpSet Jun. 26 at 11:08 PM
$LXRX
0 · Reply
SniperPro
SniperPro Jun. 26 at 10:46 PM
$LXRX So Margin Calls Are Affecting The SP Spike Too!!! 🤣🤣🤣 New requirement: 100% BOOM 💥 06/26/2026 YOU KNOW WHO IS NOT WORRIED? MEEEE!🙃 "Special Margin Maintenance Requirement change The maintenance requirement for your holding below has changed. This may increase or decrease your available purchasing power. Account: BIG BALLS- STEEL CORE NYC 🤣🐳💰 Holding Ticker Symbol: LXRX Holding Description: LEXICON PHARMACEUTICALS INC COM NEW New requirement: 100% Old requirement: 25% Please note: If you have uncovered options on this security, your requirements for those positions may also be affected."
1 · Reply
SocioCobb
SocioCobb Jun. 26 at 10:08 PM
$LXRX Beautimous!
0 · Reply
Buttermaker007
Buttermaker007 Jun. 26 at 9:31 PM
$LXRX
0 · Reply
Iman133
Iman133 Jun. 26 at 9:05 PM
$LXRX What if next week we see fillings re insiders loaded?!
2 · Reply
SniperPro
SniperPro Jun. 26 at 8:55 PM
$LXRX 39.44M SHARES SO FAR! IT'S EXCITING TO SEE THINGS MOVING IN THE RIGHT DIRECTION... WE'RE STILL SIGNIFICANTLY UNDERVALUED, SO LET'S KEEP CLIMBING TO NEW HIGHS!!! 🚀🚀🚀 Enjoy your weekend... Sniper OUT!!! ...
1 · Reply